Consensus Medpace Holdings, Inc.

Equities

MEDP

US58506Q1094

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
386.3 ^USD	+0.17%		-1.08%	+26.04%

May. 29	Medpace Holdings Insider Sold Shares Worth $3,828,058, According to a Recent SEC Filing	MT
May. 29	TD Cowen Starts Medpace Holdings With Buy Rating, $452 Price Target	MT

Evolution of the average Target Price on Medpace Holdings, Inc.

Price target over the last 5 years

History of analyst recommendation changes

56e58db96ea3cbe296d07b2484e1b1d.3iRbw6G0uonaubB0kwHk34pu8DUG9_DSG6ohDEGqVGc.5hwapOTS6uGg2vY40Uuxh70omlg0hZXkc8xAeXiHAT-xExya69rt_-KO3w~95da5ba89dd97aaeeb2fd7e547b48a60

Analyst Recommendations on Medpace Holdings, Inc.

Medpace Holdings Insider Sold Shares Worth $3,828,058, According to a Recent SEC Filing	May. 29	MT
TD Cowen Starts Medpace Holdings With Buy Rating, $452 Price Target	May. 29	MT
Mizuho Starts Medpace Holdings With Buy Rating, $435 Price Target	May. 28	MT
Medpace Holdings Insider Sold Shares Worth $1,608,764, According to a Recent SEC Filing	May. 22	MT
Medpace Holdings Insider Sold Shares Worth $15,924,222, According to a Recent SEC Filing	May. 17	MT
Medpace Holdings Insider Sold Shares Worth $1,996,723, According to a Recent SEC Filing	May. 14	MT
Medpace Holdings Insider Sold Shares Worth $21,129,347, According to a Recent SEC Filing	May. 08	MT
Medpace Holdings Insider Sold Shares Worth $6,553,671, According to a Recent SEC Filing	May. 03	MT
Medpace Holdings Insider Sold Shares Worth $6,782,987, According to a Recent SEC Filing	May. 01	MT
Baird Adjusts Medpace Price Target to $454 From $446, Maintains Outperform Rating	Apr. 24	MT
Jefferies Upgrades Medpace Holdings to Buy, Price Target at $450	Apr. 23	MT
Deutsche Bank Initiates Coverage on Medpace With Hold Rating, $395 Price Target	Mar. 18	MT
UBS Adjusts Medpace Price Target to $480 From $452, Maintains Buy Rating	Mar. 08	MT
UBS Upgrades Medpace to Buy From Neutral, Adjusts Price Target to $452 From $282	Feb. 15	MT
UBS Adjusts Medpace Price Target to $282 From $270, Maintains Neutral Rating	23-10-25	MT
Baird Upgrades Medpace Holdings to Outperform From Neutral, Adjusts Price Target to $289 From $270	23-10-24	MT
UBS Adjusts Medpace Price Target to $270 From $215, Maintains Neutral Rating	23-07-26	MT
Guggenheim Raises Medpace Holdings' Price Target to $273 From $252, Keeps Buy Rating	23-07-25	MT
Guggenheim Upgrades Medpace Holdings to Buy From Neutral, Price Target is $252	23-05-08	MT
UBS Lowers Price Target on Medpace to $215 From $238, Keeps Neutral Rating	23-04-10	MT
UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $238 From $142	22-10-27	MT
Baird Adjusts Medpace Holdings' Price Target to $217 From $200, Keeps Neutral Rating	22-10-26	MT
Baird Adjusts Price Target on Medpace Holdings to $200 From $145, Maintains Neutral Rating	22-10-25	MT
UBS Initiates Coverage on Medpace Holdings With Sell Rating, $142 Price Target	22-09-07	MT
Baird Lowers Price Target for Medpace Holdings to $137 From $151, Maintains Neutral Rating	22-06-13	MT